Crescent Biopharma (CBIO) Shares Outstanding (Diluted Average) (2013 - 2024)

Crescent Biopharma (CBIO) has 10 years of Shares Outstanding (Diluted Average) data on file, last reported at $64.5 million in Q4 2024.

• Shares Outstanding (Diluted Average) for Q4 2024 came in at $64.5 million, up 1.79% year-over-year; the trailing twelve-month figure through Dec 2024 was $64.5 million (up 1.79% YoY), and the FY2024 annual result was $64.5 million, up 1.79% from the prior year.
• Shares Outstanding (Diluted Average) was little changed at $64.5 million in Q4 2024 per CBIO's latest filing, from $64.5 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $64.5 million in Q1 2024 and troughed at $45.7 million in Q4 2020.
• A 5-year average of $57.1 million and a median of $52.5 million in 2022 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Diluted Average) rose 23.17% in 2023, then climbed 0.1% in 2024.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $45.7 million in 2020, then climbed by 12.54% to $51.5 million in 2021, then advanced by 2.1% to $52.5 million in 2022, then climbed by 20.58% to $63.3 million in 2023, then climbed by 1.79% to $64.5 million in 2024.
• Business Quant data shows CBIO's Shares Outstanding (Diluted Average) at $64.5 million in Q4 2024, $64.5 million in Q3 2024, and $64.5 million in Q2 2024.